Chronic Mild Stress Induces Fluoxetine-Reversible Decreases in Hippocampal and Cerebrospinal Fluid Levels of the Neurotrophic Factor S100B and Its Specific Receptor
Chronic mild stress (CMS) affects the hippocampal structure and function in the rat. S100B, a calcium-binding protein secreted by astrocytes, has been shown to be increased in serum of patients with depression and associated with good therapeutic response and clinical outcome. This work aimed to study the impact of CMS and fluoxetine on depressive-like behaviors in rats, as well as the concomitant expression of the astroglial protein S100B and of its receptor RAGE (receptor for advanced glycation end products) in the hippocampus and Cerebrospinal fluid of the same group of animals. S100B and sRAGE (circulating soluble form of RAGE) were measured in CSF by ELISA, and S100B and RAGE were measured in hippocampal slices by Western blot. Our study has demonstrated that stress and depression decrease S100B and RAGE/SRAGE expression and antidepressant treatment reverses or blocks these effects. This result suggested that S100B/RAGE interactions may be involved in the development and maintenance of depression and may play an important role in the mechanism of antidepressants’ therapeutic action.
References
[1]
Rajkowska, G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 2000, 48, 766–777.
[2]
Arolt, V; Peters, M; Erfurth, A; Wiesmann, M; Missler, U; Rudolf, S; Kirchner, H; Rothermundt, M. S100B and response to treatment in major depression: a pilot study. Eur. Neuropsychopharmacol 2003, 13, 235–239.
[3]
Dietrich, DE; Hauser, U; Peters, M; Zhang, Y; Wiesmann, M; Hasselmann, M; Rudolf, S; Jüngling, H; Kirchner, O; Münte, T; Arolt, V; Emrich, HM; Sonke, J; Rothermundt, M. Target evaluation processing correlates with serum levels of nerve tissue protein S100B in patients with remitted major depression. Neurosci. Lett 2004, 354, 69–73.
[4]
Veena, J; Srikumar, BN; Raju, TR; Shankaranarayana Rao, BS. Exposure to enriched environment restores the survival and differentiation of new born cells in the hippocampus and ameliorates depressive symptoms in chronically stressed rats. Neurosci. Lett 2009, 455, 178–182.
[5]
Akhisaroglu, M; Manev, R; Akhisaroglu, E; Uz, T; Manev, H. Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport 2003, 14, 1471–1473.
[6]
Tramontina, AC; Tramontina, F; Bobermin, LD; Zanotto, C; Souza, DF; Leite, MC; Nardin, P; Gottfried, C; Gon？alves, CA. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1580–1583.
[7]
Donato, R; Rauvala, H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem 2000, 275, 40096–40105.
[8]
Hofmann, MA; Drury, S; Fu, C; Qu, W; Taguchi, A; Lu, Y; Avila, C; Kambham, N; Bierhaus, A; Nawroth, P; Neurath, MF; Slattery, T; Beach, D; McClary, J; Nagashima, M; Morser, J; Stern, D; Schmidt, AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97, 889–901.
[9]
Huttunen, HJ; Kuja-Panula, J; Sorci, G; Agneletti, AL; Schmidt, AM; Yan, SD; Yan, SF; Stern, DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 2000, 1498, 99–111.
[10]
Santilli, F; Vazzana, N; Bucciarelli, LG; Davi, G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem 2009, 16, 940.
[11]
Surget, A; Saxe, M; Leman, S; Ibarguen-Vargas, Yadira; Chalon, S; Griebel, G; Hen, R; Belzung, C. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol. Psychiatry 2008, 64, 293–301.
[12]
van Eldik, LJ; Wainwright, MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor. Neurol. Neurosci 2003, 21, 97–108.
[13]
Sakatani, S; Seto-Ohshima, A; Shinohara, Y; Yamamoto, Y; Yamamoto, H; Itohara, S; Hirase, H. Neural-activity-dependent release of S100B from astrocytes enhances kainate-induced gamma oscillations in vivo. J. Neurosci 2008, 43, 10928–10936.
[14]
Sakatani, S; Seto-Ohshima, A; Itohara, S; Hirase, H. Impact of S100B on local field potential patterns in anesthetized and kainic acid-induced seizure conditions in vivo. Eur. J. Neurosci 2007, 25, 1144–1154.
[15]
Tramontina, AC; Tramontina, F; Bobermin, LD; Zanotto, C; Souza, DF; Leite, MC; Nardin, P; Gottfried, C; Gon？alves, CA. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1580–1583.
[16]
Newton, SS; Duman, RS. Regulation of neurogenesis and angiogenesis in depression. Curr. Neurovasc. Res 2004, 1, 261–267.
[17]
Magdalena, NJ; Christina, FB; Mark, JW; Ove, W. The number of granule cells in rat hippocampus is reduced after chronic mild stress and re-established after chronic escitalopram treatment. Neuropharmacology 2008, 54, 530–541.
[18]
Kleindienst, A; McGinn, MJ; Harvey, HB; Colello, RJ; Hamm, RJ; Bullock, MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J. Neurotrauma 2005, 22, 645–655.
[19]
Donato, R. S100: a multigenetic family of calcium-modulated proteins of EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol 2001, 33, 637–668.
[20]
Grabe, HJ; Ahrens, N; Rose, HJ; Keller, C; Freyberger, HJ. Neurotrophic factor S100beta in major depression. Neuropsychobiology 2001, 44, 88–90.
[21]
Rothermundt, M; Peters, M; Prehn, JHM; Arolt, V. S100B in brain damage and neurodegeneration. Microsc. Res. Tech 2003, 60, 614–632.
[22]
Manev, R; Uz, T; Manev, H. Fluoxetine increases the content of neurotrophic protein S100b in the rat hippocampus. Eur. J. Pharmacol 2001, 420, R1–R2.
[23]
Malberg, JE; Eisch, AJ; Nestler, EJ; Duman, RS. Chronic antidepressant treatment increases neurogenesis in a subunit adult rat hippocampus. J. Neurosci 2000, 20, 9104–9110.
[24]
Shi Fang, Y; Ravichandran, R; Ann, MS. Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem. Pharmacol 2010, 79, 1379–1386.
[25]
Wittkowski, H; Hirono, K; Ichida, F; Vogl, T; Ye, F. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007, 56, 4174–4181.
[26]
Strekalova, T; Spanagel, R; Bartsch, D; Henn, FA. Gass, P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 2004, 29, 2007–2017.
[27]
Bergstrom, A; Jayatissa, MN; M？rk, A; Wiborg, O. Stress sensitivity and resilience in the chronic mild stress rat model of depression: an in situ hybridization study. Brain Res 2008, 27, 41–52.
[28]
Grippo, AJ; Beltz, TG; Weiss, RM; Johnson, AK. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol. Psychiatry 2006, 59, 309–316.
[29]
Itoh, T; Tokumura, M; Abe, K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE binding activity and BDNF level in learned helplessness rats. Eur. J. Pharmacol 2004, 498, 135–142.
[30]
Sakatani, S; Yamada, K; Homma, C; Munesue, S; Yamamoto, Y; Yamamoto, H; Hirase, H. Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice. PLoS One 2009, 15, 8309.
[31]
Willner, P; Towell, A; Sampson, D; Sophokleous, S; Muscat, R. Reduction of sucrose preference by chronic unpredictable mild stress and its restoration by a tricyclic antidepressant. Psychopharmacology 1987, 93, 358–364.
[32]
Pardon, MC; Perez-Diaz, F; Joubert, C; Cohen-Salmon, C. Influence of chronic ultramild stress procedure on decision-making in mice. J. Psychiatry Neurosci 2000, 25, 167–177.
